LB934 Metastatic squamous cell carcinoma is associated with a lower disease-specific survival in immunosuppressed patients: A matched case-control study

Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer with over 1 million cases and an estimated 3,932 to 8,791 deaths each year in United States. cSCC patients have a 1-3% chance of developing metastasis which increases 7-13% immunosuppressed patients. The new 8th edition American Joint Committee on Cancer (AJCC8) classification system currently used stage cSCC, however immunosuppression not included as staging criterion. A review diagnosis seen at tertiary referral center was conducted from 2010-2020. Pathology database yielded five metastatic known primary tumor immunosuppression. These were 2:1 case-matched using age, gender, diameter 3 other cohorts: non-metastatic immunocompetent primary, SCC. majority had T T3. Immunosuppressed worse prognosis for survival compared their counterparts or those disease only 50% disease-specific (DSS) one year. 90% (p<0.0001). 40% decline probability when suggests that important risk factor determining DSS should be taken into account caring these individuals.